To evaluate the efficacy and safety of B007 in the Treatment of Primary Membranous Nephropathy
Subjects with primary membranous nephropathy pathologically confirmed by renal biopsy;
Subjects with glomerular filtration rate（eGFR） ≥ 45 mL/min/1.73 m2.
If taking Angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists/sodium-glucose cotransporter 2 inhibitors/endothelin inhibitors, a stable dose within 4 weeks before randomization;
Subjects with 24-hour elevated urinary protein in accordance with the prescribed conditions;
Subjects with secondary membranous nephropathy or primary membranous nephropathy whose pathological reports suggest concomitant crescent bodies;
Subjects identified by the investigator as previously resistant to CD20 monoclonal antibody or cyclosporine;
Subjects who have received medication prescribed for membranous nephropathy;
Subjects with concomitant prescribed diseases;
Shanghai Jiaolian Drug Research and Development Co., Ltd
Lead sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Collaborator